BIO Bio-Rad Laboratories Inc: Multiplikator forward rega marang pendapatan

Logo korporat perusahaan bio-rad.com (BIO)

High barriers to entry driven by proprietary systems provide Bio-Rad Laboratories (BIO) with a stable income stream. Forward EV/Revenue visualization captures these trends, where the value of 13.80 expresses the metric level. Business resilience relies on recurring consumable sales, which guarantee a steady cash flow. Simultaneously, Bio-Rad Laboratories (BIO) is implementing energy-efficient equipment and eco-friendly reagents in adherence to strict ESG standards.

BIO bio-rad.com: Rega forward marang dodolan ing interval 04.07.2022 - 13.11.2026

Bio-Rad Corp - rincian analitis lan metrik utama (BIO)

- rega pasar lan target rega analis:
Ringkesan analisis perusahaan:BIO (Bio-Rad)
Sampel barang bio-rad.com

To find a balance between operational risks and return on equity, it is essential to consider the specifics of Bio-Rad Laboratories (BIO), where the high inertia of closed blood analysis systems ensures a stable revenue stream from reagents. By analyzing the forward P/S metric, an investor assesses the current market value of Bio-Rad Laboratories (BIO) relative to expected revenue volumes, confirming the business's fundamental stability over the long term.

Karo sapa Bio-Rad Laboratories saingan

Rasio rega marang prakiraan pendapatan Agilent A|Quest Diagnostics Inc. (DGX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ILMN: Multiplikator forward rega marang pendapatan|Prakiraan rega marang pendapatan Exact Sciences Inc. (EXAS)|Revvity, Inc. (RVTY) - Rasio rega marang prakiraan pendapatan|anbio.com - Rega forward marang dodolan|SHC (Sotera Health) - Multiplikator Forward P/S|Multiplikator Forward P/S Quidel Corporation|Multiplikator Forward P/S OPK|CareDx Health - Kapitalisasi marang prakiraan pendapatan|Maravai LifeSciences - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan FLGT|LAB - Rasio rega marang prakiraan pendapatan|CTKB: Rasio rega marang prakiraan pendapatan|OSUR: Multiplikator Forward P/S|Exagen (XGN) - Multiplikator Forward P/S|MDXH (MDxHealth SA) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan LUCD|Rasio rega marang prakiraan pendapatan Prenetics Global (PRE)|IMDX - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Trinity Biotech TRIB|Rega forward marang dodolan PRPH|Ainos, Inc. - Multiplikator Forward P/S|CODX - Multiplikator Forward P/S|HSCS (HeartSciences) - Multiplikator forward rega marang pendapatan|BMRA: Rasio rega marang pendapatan sing dikarepake|Rasio rega marang prakiraan pendapatan Cardio Diagnostics Holdings Inc.|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Onconetix Corporation ONCO|Rasio rega marang prakiraan pendapatan Virax Biolabs Group (VRAX)|BJDX (bluejaydx.com) - Rega forward marang dodolan|Multiplikator Forward P/S AWH (Aspira Women's Health Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake Accelerate Diagnostics Inc. (AXDX)|centogene.com - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Enzo Biochem, Inc.|fresh2.co (FRES) - Rasio rega marang prakiraan pendapatan|GENE - Rasio kapitalisasi marang dodolan sing dikarepake|ME (23andMe) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan PMD